Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insufficient Sleep and Sleep Deprivation01:13

Insufficient Sleep and Sleep Deprivation

1.3K
Insufficient sleep refers to not getting the recommended amount of sleep for optimal functioning, even if it's just slightly less than needed. Sleep insufficiency may occur due to lifestyle choices, such as staying up late for social events or work, resulting in routinely getting less sleep than required. For example, consistently sleeping 6 hours when the body needs 7-9 hours can lead to cumulative effects on health and well-being.
Sleep deprivation is a more severe form of sleep loss...
1.3K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.2K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

343
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
343
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

887
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
887
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

394
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
394
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship01:14

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

99
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
99

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic Syndrome and Obstructive Sleep Apnea: Two Sides of the Same Coin.

Sleep·2026
Same author

Adenotonsillectomy in Children With Mild to Moderate Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis.

Pediatric pulmonology·2026
Same author

Generalizability of symptom-based subtypes of moderate to severe OSA patients within and between ethnic groups.

Annals of the American Thoracic Society·2026
Same author

Meta-analysis of diagnostic test accuracy of pediatric sleep questionnaire and the OSA-18 questionnaire in the screening of pediatric obstructive sleep apnea.

Sleep medicine·2026
Same author

Placebo and nocebo responses in gabapentin enacarbil and pregabalin trials for restless legs syndrome: time-course model-based network meta-analysis and meta-analysis of proportions.

Sleep & breathing = Schlaf & Atmung·2026
Same author

Benefit-risk comparison of gabapentin enacarbil versus pregabalin for restless legs syndrome: A dose-response model-based network meta-analysis.

Sleep & breathing = Schlaf & Atmung·2026

Related Experiment Video

Updated: Apr 7, 2026

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

1.7K

Sleep Duration and Metabolic Syndrome. An Updated Dose-Risk Metaanalysis.

Imran H Iftikhar1,2, Meredith A Donley2, Jesse Mindel1

  • 11 Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio; and.

Annals of the American Thoracic Society
|July 14, 2015
PubMed
Summary
This summary is machine-generated.

Short sleep duration increases the risk of metabolic syndrome, with less than 5 hours of sleep linked to 1.5 times higher odds. Long sleep duration was not significantly associated with metabolic syndrome in this meta-analysis.

Keywords:
metaanalysismetabolic syndromesleep duration

More Related Videos

An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment
10:31

An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment

Published on: April 20, 2018

11.3K
Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

12.4K

Related Experiment Videos

Last Updated: Apr 7, 2026

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

1.7K
An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment
10:31

An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment

Published on: April 20, 2018

11.3K
Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

12.4K

Area of Science:

  • Metabolic health
  • Sleep science
  • Epidemiology

Background:

  • Previous research indicates associations between both short and long sleep durations and metabolic syndrome.
  • The existence of a dose-response relationship between sleep duration and metabolic syndrome remains unclear.

Purpose of the Study:

  • To conduct a meta-analysis to quantify the association between various sleep durations and the prevalence of metabolic syndrome.
  • To investigate the dose-response relationship between sleep duration and metabolic syndrome.

Main Methods:

  • A systematic literature search was conducted in PubMed, Web of Science, and Ovid.
  • Included were cross-sectional studies analyzing the association between sleep duration and metabolic syndrome, up to October 4, 2014.
  • Data from 18 studies involving 75,657 participants were analyzed.

Main Results:

  • A significant dose-response relationship was observed between short sleep duration (<7 hours) and an increased odds of metabolic syndrome.
  • Individuals sleeping less than 5 hours had an odds ratio (OR) of 1.51 for metabolic syndrome.
  • Sleep durations of 5-6 hours (OR=1.28) and 6-7 hours (OR=1.16) also showed increased odds compared to 7-8 hours.
  • No significant association was found between long sleep duration and metabolic syndrome (OR=1.13).

Conclusions:

  • A clear dose-response relationship exists, confirming that shorter sleep durations significantly elevate the risk of metabolic syndrome.
  • Sleeping less than 5 hours per night presents a substantially higher odds of developing metabolic syndrome.
  • The current meta-analysis does not provide evidence to support an association between long sleep duration and metabolic syndrome.